All In Biotech

Drug Trial Radar · NCT03693131

Efficacy of MND-2119 in Participants With Hypertriglyceridemia

MND-2119 Phase 3 Study to Evaluate the Efficacy and Safety of MND-2119 Compared to EPADEL CAPSULES 300 in Patients With Hypertriglyceridemia

Last checked: Nov 20, 2026Latest source record: Aug 1, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 580 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

580

Actual

Start

Oct 27, 2018

Primary completion

Jun 15, 2019

Study completion Jun 29, 2019

Sponsor

Sponsor type
Industry
First posted
Oct 2, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 20 years, up to 74 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of MND-2119 compared to EPADEL CAPSULES 300 in participants with hypertriglyceridemia.

Conditions

  • Hypertriglyceridemia

Interventions

  • Icosapent (MND-2119)Drug

    Icosapent (MND-2119) capsules.

  • Icosapent (EPADEL CAPSULES 300)Drug

    Icosapent (EPADEL CAPSULES 300) capsules.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of change from baseline in serum triglyceride level at 12 weeks after the start of study drug administrationTime frame: Baseline and 12 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Mochida Investigational sites

    Tokyo, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.